X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
A vaccine candidate, is being investigated in a phase 2 trial in above 2 years older Nigerian population for the prevention of Lassa fever virus infection.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: HJF Medical Research International
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2024
Details:
The net proceeds will be used to conduct a Phase IIb trial assessing the safety and efficacy of the tuberculosis (TB) vaccine candidate MTBVAC to prevent active TB lung disease in adolescents and adults.
Lead Product(s): MTBVAC
Therapeutic Area: Infections and Infectious Diseases Product Name: MTBVAC
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Funding December 18, 2023
Details:
The funding will support the late-stage development of MTBVAC, a live, attenuated Mycobacterium tuberculosis vaccine, currently being developed as a potentially longer-lasting TB vaccine for newborns and for the prevention of TB disease in adults and adolescents.
Lead Product(s): MTBVAC
Therapeutic Area: Infections and Infectious Diseases Product Name: MTBVAC
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: German government
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Funding July 07, 2023
Details:
IAVI C108 (rVSV∆G-SUDV-GP) vaccine candidate for Sudan ebolavirus disease prevention, consisting of replicating vesicular stomatitis vector containing a Sudan ebolavirus glycoprotein immunogen.
Lead Product(s): rVSV∆G-SEBOV-GP Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: IAVI C108
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Biomedical Advanced Research and Development Authority
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
Under the agreement, IAVI is supporting development, global regulatory strategy, resource mobilization, and access planning for the adolescent/adult tuberculosis (TB) vaccine candidate MTBVAC.
Lead Product(s): MTBVAC
Therapeutic Area: Infections and Infectious Diseases Product Name: MTBVAC
Highest Development Status: Phase IIIProduct Type: Vaccine
Recipient: Biofabri
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 17, 2023
Details:
The funding will be used in the development and testing of IAVI's single-dose vaccine candidates, rVSVΔG-MARV-GP and rVSVΔG-SUDV-GP, against the filoviruses Marburg virus (MARV) and Sudan ebolavirus (SUDV) respectively.
Lead Product(s): rVSVΔG-MARV-GP
Therapeutic Area: Infections and Infectious Diseases Product Name: rVSVΔG-MARV-GP
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: BARDA
Deal Size: $47.0 million Upfront Cash: Undisclosed
Deal Type: Funding March 02, 2023
Details:
IAVI holds a nonexclusive license to the VSV vaccine candidates (having rVSV∆G-LASV-GPC) from the Public Health Agency of Canada (PHAC). The vector was developed by scientists at PHAC’s National Microbiology Laboratory.
Lead Product(s): rVSV∆G-LASV-GPC
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 25, 2022
Details:
mRNA-1644 (eOD-GT8 60mer mRNA Vaccine) engineered HIV envelope proteins delivered through messenger RNA and designed to target germline B cells and guide their maturation toward the development of neutralizing antibody responses.
Lead Product(s): eOD-GT8 60mer mRNA Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: mRNA-1644
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
The collaboration combines, Moderna's mRNA platform and IAVI's expertise in discovery and product development to advance vaccines and antibodies. Within partnership, program in development is Phase I clinical trial, IAVI G002, of HIV vaccine, eOD-GT8 60mer.
Lead Product(s): eOD-GT8 60mer
Therapeutic Area: Infections and Infectious Diseases Product Name: eOD-GT8 60mer
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 07, 2022
Details:
A Phase 1, randomized, first-in-human, open-label study to evaluate the safety and immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) in HIV-1 uninfected adults in good general health.
Lead Product(s): mRNA-1644
Therapeutic Area: Infections and Infectious Diseases Product Name: mRNA-1644
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
